Remission of idiopathic nephrotic syndrome after treatment with cyclosporin A

British Medical Journal (Clinical research ed.)

Volumn 292, Issue 6523, 1986, Pages 789-792

  Meyrier, Alain ^a   Simon, Pierre ^b   Perret, Gerard ^a   Condamin Meyrier, Marie Claude ^a  

^a AVICENNE HOSPITAL   (France)

^b Hdpital la Bauchee ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; METHYLPREDNISOLONE; PREDNISONE;

CLINICAL ARTICLE; DIAGNOSIS; DRUG EFFICACY; DRUG THERAPY; ETIOLOGY; FOCAL GLOMERULOSCLEROSIS; GLOMERULOSCLEROSIS; HUMAN; IDIOPATHIC NEPHROTIC SYNDROME; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY; KIDNEY DISEASE; METHODOLOGY; MINIMAL CHANGE GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; ORAL DRUG ADMINISTRATION; PRELIMINARY COMMUNICATION; PRIORITY JOURNAL; PROTEINURIA; THERAPY;

ADULT; BODY WEIGHT; CASE REPORT; CREATININE; CYCLOSPORINS; FEMALE; HUMAN; MALE; MIDDLE AGE; NEPHROTIC SYNDROME; PROTEINURIA; SERUM ALBUMIN; SODIUM;

EID: 0022617211     PISSN: 02670623     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.292.6523.789     Document Type: Article

References (23)

1. Heptinstall, RH, ed. The nephrotic syndrome. In: Pathology of the kidney. VoI2. 3rd ed. Boston: Little Brown and Co, 1983:637–740.
2. International Study of Kidney Disease in Children. Nephrotic syndrome in children: a randomized trial comparing two prednisone regimens in steroid-responsive patients who relapse early. JPediatr 1979;95:239–243.
3. Anonymous. Immunosuppression in the nephrotic syndrome [Editorial]. Lancet 1976;i:1121–1122.
4. Brown, CB, Cameron, JS, Turner, DR, et al. Focal segmental glomerulosclerosis with rapid decline in renal function (“malignant FSGS”). Clin Nephrol 1978;10:51–61.
5. Hoyer, JR, Raij, L, Vernier, RL, et al. Recurrence of idiopathic nephrotic syndrome after renal transplantation. Lancet 1972;ii:34–35.
6. Lagrue, G, Xheneumont, S, Branellec, A, et al. A vascular permeability factor elaborated from lymphocytes. I. Demonstration in patients with nephrotic syndrome. Biomedicine 1975;23:37–40.
7. Zimmerman, SW. Increased urinary protein excretion in the rat produced by serum from a patient with recurrent focal glomerular sclerosis after renal transplantation. Chn Nephrol 1984;22:32–38.
8. Levin, M, Smith, C, Walters, MDS, Gascoine, P, Barratt, TM. Steroid-responsive nephrotic syndrome: a generalised disorder of membrane negative charge. Lancet 1985;ii:239–342.
9. Shalhoub, RJ. Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet 1974;ii: 556–560.
10. Fillit, HM, Zabriskie, JB. Cellular immunity in glomerulonephritis. AmJPathol 1982;109:227–243.
11. Giangiacomo, J, Cleary, TG, Cole, BR, Hoffsten, P, Robson, AM. Serum immunoglobulins in the nephrotic syndrome (a possible cause of minimal change nephrotic syndrome). N EnglJ Med 1975;293:8–12.
12. Beale, MG, Nash, GS, Bertovich, MJ, et al. Immunoglobulin synthesis by peripheral blood mononuclear cells in minimal change nephrotic syndrome. Kidney Int 1983;23:380–386.
13. Dall’aglio, P, Meroni, PL, Barcellini, W, et al. Altered expression of B lymphocyte surface immunoglobulins in minimal change nephrotic syndrome and focal glomerulosclerosis. Nephron 1984;37:224–228.
14. Kerpen, HO, Bhat, JG, Kanton, R, et al. Lymphocyte subpopulations in minimal change nephrotic syndrome. Clin Immunol Immunopathol 1979;14:130–136.
15. Mallick, NP. The pathogenesis of minimal change nephropathy. Clin Nephrol 1977;7:87–95.
16. Bunjes, D, Hardt, C, Rollinghoff, M, Wagner, H. Cyclosporin A mediates immunosuppression of primary cytotoxic T-cell responses by impairing the release of interleukin-1 and interleukin-2. EurJ Immunol 1981;11:657–661.
17. Hess, AD, Tutschka, PJ, Santos, GW. Effect of cyclosporin A on human lymphocyte responses in vitro. III. CsA inhibits the production of T lymphocyte growth factors in secondary mixed lymphocyte responses but does not inhibit the response of primed lymphocytes to TCGF. J Immunol 1982;128:355–358.
18. Kalman, VK, Klimpel, GR. Cyclosporin A inhibits the production of gammainterferon but does not inhibit production of virus-induced alpha/beta interferon. Cell Immunol 1983;78:122–129.
19. Geers, AB, Koomans, HA, Roos, JC, Boer, P, Dorhout-Mees EJ. Functional relationships in the nephrotic syndrome. Kidney hit 1984;26:324–330.
20. Ichikawa, I, Rennke, HG, Hoyer, JR, et al. Role for intrarenal mechanisms in the impaired salt excretion of experimental nephrotic syndrome. J Clin Invest 1983;71:91–103.
21. Brown, EA, Markandu, N, Sagnella, AS, Jones, BE, MacGregor, GA. Sodium retention in nephrotic syndrome is due to an intrarenal defect: evidence from steroid-induced remission. Nephron 1985;39:290–295.
22. Habib, R, Churg, J, Bernstein, J, et al. Minimal change disease, mesangial proliferative glomerulonephritis and focal sclerosis: individual entities or a spectrum of disease? In: Robinson RR, ed. Proceedings of the ninth congress of nephrology. Vol 1. Berlin: Springer-Verlag, 1984:634–644.
23. Vanrenterghem, Y, Roels, L, Lerut, T, et al. Thromboembolic complications and haemostatic changes in cyclosporin-treated cadaveric kidney allograft recipients. Lancet 1985;i:999–1002.